IPP Bureau
Health Minister Nadda inaugurates Medicine Update BJMFCON 2024
By IPP Bureau - October 21, 2024
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Senores Pharmaceuticals gets SEBI nod for IPO
By IPP Bureau - October 21, 2024
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
By IPP Bureau - October 21, 2024
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi
By IPP Bureau - October 21, 2024
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
By IPP Bureau - October 21, 2024
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
By IPP Bureau - October 21, 2024
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg
By IPP Bureau - October 19, 2024
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets
By IPP Bureau - October 19, 2024
Granules now has a total of 67 ANDA approvals from the USFDA
Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study
By IPP Bureau - October 19, 2024
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
By IPP Bureau - October 19, 2024
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Gland Pharma appoints Shyamakant Giri as CEO
By IPP Bureau - October 19, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
AstraZeneca advances science of infectious disease protection at IDWeek 2024
By IPP Bureau - October 18, 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
FDA approves VYALEV for adults living with advanced parkinson's disease
By IPP Bureau - October 18, 2024
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome completes 10 years in genomics in India
By IPP Bureau - October 18, 2024
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Lupin launches first generic of Pred Forte in US
By IPP Bureau - October 16, 2024
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
